Cargando…
Cost evaluation of the Merlin assay for predicting melanoma sentinel lymph node biopsy metastasis
BACKGROUND: The Merlin assay for melanoma‐risk assessment has become commercially available to reduce the rate of unnecessary sentinel lymph node biopsies (SLNB) in SLNB‐eligible patients with cutaneous melanoma. Merlin low‐risk patients are recommended to undergo wide local excision (WLE) of the pr...
Autores principales: | Thao, Viengneesee, Dholakia, Ruchita, Moriarty, James P., Borah, Bijan J., Dwarkasing, Jvalini, Meves, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098626/ https://www.ncbi.nlm.nih.gov/pubmed/36440797 http://dx.doi.org/10.1111/ijd.16515 |
Ejemplares similares
-
Using the Merlin assay for reducing sentinel lymph node biopsy complications in melanoma: a retrospective cohort study
por: Hieken, Tina J., et al.
Publicado: (2022) -
Validation of CP‐GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: A U.S. cohort study
por: Yousaf, Ahmed, et al.
Publicado: (2021) -
Cutaneous Melanoma and Sentinel Lymph Node Biopsy
por: van Akkooi, A. C. J., et al.
Publicado: (2008) -
Deselecting Melanoma Patients for Sentinel Lymph Node Biopsy During COVID-19: Clinical Utility of Tumor Molecular Profiling
por: Meves, Alexander, et al.
Publicado: (2020) -
Sentinel Lymph Node Biopsy and Complete Lymph Node Dissection for Melanoma
por: Falk Delgado, Alberto, et al.
Publicado: (2019)